peb announcement , page-7

I don't know at what price the shares were issued at, but this announcement should see CDY in profit.

"CELLMID RECEIVED PACIFIC EDGE MILESTONE SHARES

? Pacific Edge have issued 1,084,622 shares to Cellmid having achieved their requisite milestone

? The shares have been issued pursuant to the midkine diagnostic license agreement signed on 17 May 2010

SYDNEY, Thursday, 1 August 2013: Cellmid Limited (ASX: CDY) has been notified that it has been issued 1,084,622 milestone shares by Pacific Edge Limited (Pacific Edge).
Cellmid signed a license agreement with Pacific Edge in 2010 for the use of midkine as one of the biomarkers in their bladder cancer test (Cxbladder®). The license between Cellmid and Pacific Edge provides for a milestone fee, payable in Pacific Edge shares, and due at the time Cxbladder® sales commence in the USA. In addition to the
milestone fee royalties will also be paid to Cellmid on Cxbladder® revenues."

https://research.iress.com.au/ids/old/20130801/01430615.pdf?uid=FE1D90DF5E92EFD95B73D96EC6775EDADA210000A37BFEAB8E4BE440A97B0200AD430000&ppv=

According to RM Research report dated March 2013, we should now be trading at 7.2cps and an estimated 1.5 - 2% in royalties should grow the kitty!

"Update on Cxbladder (partnership with Pacific Edge Biodiagnostics, PEB) - We value Cxbladder at A$0.015 (+ A$0.009 from previous valuation) as test moves closer to
commercialization and we increase our estimate of the royalty rates from 1.5% to 2%.

According to most recent update from PEB’s management the company is on track to get CLIA certification by the end of March with commercial launch to follow shortly after."

http://www.cellmid.com.au/content_common/pg-analyst-coverage.seo

http://www.cellmid.com.au/SiteMedia/w3svc921/Uploads/Documents/11%20March%202013%20RM%20Research%20Report%20-%20Cellmid%20Limited.pdf